Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6586458 | CURRAX | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
Aug, 2017
(6 years ago) | |
US8022095 | CURRAX | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
Aug, 2017
(6 years ago) | |
US5872145 | CURRAX | Formulation of 5-HT agonist and NSAID for treatment of migraine |
Aug, 2017
(6 years ago) | |
US6060499 | CURRAX | Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs |
Aug, 2017
(6 years ago) | |
US6586458 (Pediatric) | CURRAX | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
Feb, 2018
(6 years ago) | |
US8022095 (Pediatric) | CURRAX | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
Feb, 2018
(6 years ago) | |
US6060499 (Pediatric) | CURRAX | Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs |
Feb, 2018
(6 years ago) | |
US5872145 (Pediatric) | CURRAX | Formulation of 5-HT agonist and NSAID for treatment of migraine |
Feb, 2018
(6 years ago) | |
US7332183 | CURRAX | Multilayer dosage forms containing NSAIDs and triptans |
Oct, 2025
(1 year, 5 months from now) | |
US7332183 (Pediatric) | CURRAX | Multilayer dosage forms containing NSAIDs and triptans |
Apr, 2026
(1 year, 11 months from now) |
Treximet is owned by Currax.
Treximet contains Naproxen Sodium; Sumatriptan Succinate.
Treximet has a total of 10 drug patents out of which 8 drug patents have expired.
Expired drug patents of Treximet are:
Treximet was authorised for market use on 14 May, 2015.
Treximet is available in tablet;oral dosage forms.
Treximet can be used as acute treatment of migraine, treatment of migraine.
The generics of Treximet are possible to be released after 02 April, 2026.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | May 14, 2018 |
Pediatric Exclusivity(PED) | Nov 14, 2018 |
Drugs and Companies using NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 14 May, 2015
Treatment: Acute treatment of migraine; Treatment of migraine
Dosage: TABLET;ORAL